The new European Regulation on Health Technology Assessment (HTA-R) 2021/2282 officially came into force on January 12, 2025, marking a significant step in the creation of a harmonized system for health technology assessment within the European Union.
The primary objective of this regulation is to facilitate patient access to effective and safe treatments by promoting a coordinated and transparent approach among the various Member States.
The new European HTA Regulation on HTA represents a pact of solidarity among the 27 countries of the European Union. It aims to improve the quality of healthcare services, reduce health inequalities, and promote the overall well-being of the European population. The regulation clearly outlines the procedures and responsibilities of the stakeholders involved, emphasizing the importance of a coordinated and transparent approach.
In this special report, we have leveraged our expertise to analyze the implications of the new European HTA Regulation and disseminate its details. The document provides a comprehensive overview of the regulatory updates published so far, including procedures, timelines, and the responsibilities of the actors involved in the new HTA system.
The implementation of HTA-r recommendations represents a significant opportunity for all stakeholders. At Pharma Value, we are ready.
This report was created with the aim of sharing valuable information and insights. If you notice any errors or changes that need to be addressed, we kindly invite you to let us know, your feedback is invaluable in improving our work.
